FDC Ban: A Step Toward Safe, Evidence-Based Prescribing Of Medicines

The Indian government has banned the manufacture, sale, and distribution of 16 Fixed Dose Combination (FDC) drugs for human use with immediate effect. The move follows a Supreme Court-directed review by an expert committee set up by the Drugs Technical Advisory Board (DTAB), which found that the drug combinations lacked therapeutic justification and could pose health risks.

The Ministry of Health and Family Welfare said the action aims to ensure only safe, effective and scientifically validated medicines remain available. State drug regulators and enforcement agencies have been directed to strictly implement the ban.

Dr. Sowmya Bondalapati, Senior Consultant - General Medicine, CARE Hospitals, Hitech City, said that the government’s decision is a positive step towards rational and evidence-based prescribing. It promotes safer, more individualized treatment and helps avoid unnecessary medications. Patients should not stop any medicine on their own but consult their doctor for appropriate alternatives if needed, she said.

For common conditions such as fever, pain, infections, stomach problems, and diabetes, doctors may increasingly prescribe individual medicines or well-established combinations with proven benefits. The focus will be on giving only the medicines that are genuinely needed, she said, and this would also allow greater flexibility in adjusting doses according to a patient's age, weight, and medical condition, while improving cost-effectiveness by avoiding unnecessary medications, Dr Soumya stated.

The main impact is improved patient safety and more rational use of medicines. In antibiotics, it can help reduce the risk of antimicrobial resistance. In pain, stomach, and diabetes medicines, it helps ensure that each medicine prescribed has a clear purpose and proven benefit, she said and assured that patients should not be concerned as the ban applies to specific combinations, not necessarily the individual medicines. Suitable alternatives remain available and can be prescribed by doctors, she stated.

A fixed-dose combination should provide a clear advantage over taking the medicines separately. Some of the banned combinations lacked sufficient scientific evidence or offered limited additional benefit. These combinations may increase the risk of side effects, drug interactions, unnecessary costs, and can make it difficult to identify which medicine is responsible if an allergic reaction occurs. They also limit a doctor's ability to adjust doses according to individual patient needs, Dr Soumya concluded.

Dr. Shivaraju, General Physician at KIMS Hospital, raised concerns over several FDCs, stating that many of them are irrational as they combine drugs with different mechanisms of action. A number of these formulations contain ingredients such as Serratiopeptidase and Clidinium Bromide. Clidinium Bromide, an anticholinergic agent, can reduce sweating and dry up body secretions, potentially increasing the risk of heat stroke, particularly in hot environments. He also explains that drugs containing Clidinium Bromide combined with Chlordiazepoxide may also cause drowsiness and dizziness, which can impair a person's ability to drive or operate machinery safely. Additionally, some FDCs include vitamins A and E, both of which are fat-soluble and can accumulate in the body with prolonged use, potentially leading to toxicity. These concerns have prompted calls for closer scrutiny of the safety and therapeutic rationale behind such combinations, Dr Shivaraju stated.

Dr. Mithil Ghushe, Consultant Internal Medicine at Medicover Hospitals, Hitec City also reiterates that the ban on certain FDCs is a positive step towards promoting rational drug use and patient safety. “In the case of antibiotic combinations, it will help curb the inappropriate use of antibiotics and reduce the growing threat of antimicrobial resistance. Several of these combinations offered limited additional benefit while exposing patients to unnecessary risks,” he remarked.

Dr. Mithil also states that antibiotic combinations are particularly concerning because irrational use can accelerate antimicrobial resistance, which is one of the biggest public health challenges worldwide. Similarly, in conditions such as diabetes and chronic pain, fixed combinations may limit a doctor's ability to adjust doses according to a patient's individual needs.

For antispasmodic drugs, the ban encourages a more targeted approach to treatment, ensuring that medications are prescribed based on the specific cause of symptoms. Similarly, cosmetic and topical products marketed as medicines must have proven therapeutic value and scientific evidence to support their use, continued Dr Mithil.

“When it comes to diabetes and pain management, the move allows us physicians’ greater flexibility to individualize treatment according to the patient's condition rather than relying on fixed combinations that may not suit everyone, he explained.

From a medical standpoint, a “Fixed Dose Combination” is considered rational only when each ingredient contributes significantly to the intended therapeutic effect and the combination offers a proven advantage over using the drugs separately. Many of the banned FDCs failed to meet these criteria, he stated.

Several combinations lacked robust scientific evidence demonstrating improved efficacy or safety. In some cases, additional ingredients did not provide meaningful clinical benefits but increased the risk of side effects, drug interactions, unnecessary medication exposure, and treatment complications.

From a medical perspective, any medicine must have a clear therapeutic purpose, an established safety profile, and proven clinical benefit. If a combination lacks these qualities or poses avoidable risks to patients, it may be classified as irrational and unsuitable for continued use. The ban reflects the healthcare system's commitment to ensuring that patients receive safe, effective, and scientifically validated treatments."

Overall, this decision is expected to improve treatment quality, reduce adverse drug reactions, and strengthen evidence-based prescribing practices, Dr Mithil concluded.